Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time
Aditxt (NASDAQ: ADTX) has announced a stakeholder update and Q&A session scheduled for Friday, October 11, 2024, at 11:30 AM EDT. CEO Amro Albanna will lead the session, covering:
- Company overview and updates on Evofem and Appili transactions
- Current programs in immune and precision health
- Year-end roadmap for 2024
- Q&A segment addressing pre-submitted questions
Aditxt operates two programs focused on immune health and precision health, with plans to introduce two additional programs in public health and women's health. The company has entered into agreements with Appili Therapeutics and Evofem Biosciences for these new programs. Aditxt's innovation platform aims to accelerate promising health innovations through collaboration with research institutions, industry partners, and shareholders.
Aditxt (NASDAQ: ADTX) ha annunciato un aggiornamento per gli stakeholder e una sessione di domande e risposte programmata per venerdì 11 ottobre 2024, alle 11:30 EDT. Il CEO Amro Albanna guiderà la sessione, che tratterà:
- Panoramica dell'azienda e aggiornamenti sulle transazioni Evofem e Appili
- Programmi attuali in salute immune e salute di precisione
- Roadmap di fine anno per il 2024
- Sezione di domande e risposte che affronta domande inviate in anticipo
Aditxt gestisce due programmi incentrati sulla salute immunitaria e sulla salute di precisione, con piani per introdurre due programmi aggiuntivi in salute pubblica e salute delle donne. L'azienda ha stipulato accordi con Appili Therapeutics ed Evofem Biosciences per questi nuovi programmi. La piattaforma d'innovazione di Aditxt mira ad accelerare le promettenti innovazioni sanitarie attraverso la collaborazione con istituzioni di ricerca, partner industriali e azionisti.
Aditxt (NASDAQ: ADTX) ha anunciado una actualización para los interesados y una sesión de preguntas y respuestas programada para el viernes 11 de octubre de 2024, a las 11:30 AM EDT. El CEO Amro Albanna dirigirá la sesión, que cubrirá:
- Descripción de la empresa y actualizaciones sobre las transacciones de Evofem y Appili
- Programas actuales en salud inmunológica y salud de precisión
- Hoja de ruta para finales de año 2024
- Segmento de preguntas y respuestas que aborda preguntas enviadas con anticipación
Aditxt opera dos programas centrados en la salud inmunológica y la salud de precisión, con planes para introducir dos programas adicionales en salud pública y salud de la mujer. La empresa ha establecido acuerdos con Appili Therapeutics y Evofem Biosciences para estos nuevos programas. La plataforma de innovación de Aditxt tiene como objetivo acelerar las innovaciones en salud prometedoras a través de la colaboración con instituciones de investigación, socios de la industria y accionistas.
Aditxt (NASDAQ: ADTX)는 2024년 10월 11일 금요일, 오전 11:30 EDT에 예정된 이해관계자 업데이트 및 Q&A 세션을 발표했습니다. CEO Amro Albanna가 세션을 이끌며 다음 내용을 다룹니다:
- 회사 개요 및 Evofem, Appili 거래에 대한 업데이트
- 면역 건강 및 정밀 건강에 대한 현재 프로그램
- 2024년 연말 로드맵
- 사전 제출된 질문을 다루는 Q&A 세그먼트
Aditxt는 면역 건강 및 정밀 건강에 초점을 맞춘 두 개의 프로그램을 운영하고 있으며, 공공 건강 및 여성 건강에 대한 두 개의 추가 프로그램을 도입할 계획입니다. 이 회사는 이러한 새로운 프로그램을 위해 Appili Therapeutics 및 Evofem Biosciences와 협약을 체결했습니다. Aditxt의 혁신 플랫폼은 연구 기관, 산업 파트너 및 주주와의 협력을 통해 유망한 건강 혁신을 가속화하는 것을 목표로 하고 있습니다.
Aditxt (NASDAQ: ADTX) a annoncé une mise à jour pour les parties prenantes et une session de questions-réponses prévue pour vendredi 11 octobre 2024, à 11h30 EDT. Le PDG Amro Albanna animera la session, qui couvrira :
- Présentation de l'entreprise et mises à jour concernant les transactions avec Evofem et Appili
- Programmes actuels en matière de santé immunitaire et de santé de précision
- Feuille de route de fin d'année pour 2024
- Segment de questions-réponses traitant des questions soumises à l'avance
Aditxt gère deux programmes axés sur la santé immunitaire et la santé de précision, avec des projets d'introduction de deux programmes supplémentaires en santé publique et santé des femmes. L'entreprise a conclu des accords avec Appili Therapeutics et Evofem Biosciences pour ces nouveaux programmes. La plateforme d'innovation d'Aditxt vise à accélérer les innovations prometteuses en santé grâce à une collaboration avec des institutions de recherche, des partenaires industriels et des actionnaires.
Aditxt (NASDAQ: ADTX) hat ein Update für die Stakeholder und eine Fragen-und-Antworten-Sitzung angekündigt, die für Freitag, den 11. Oktober 2024, um 11:30 Uhr EDT geplant ist. CEO Amro Albanna wird die Sitzung leiten, die folgende Themen behandelt:
- Unternehmensübersicht und Updates zu den Transaktionen von Evofem und Appili
- Aktuelle Programme in der Immun- und Präzisionsgesundheit
- Jahresend-Roadmap für 2024
- Q&A-Teil, der vorab eingereichte Fragen behandelt
Aditxt betreibt zwei Programme, die sich auf die Immun- und Präzisionsgesundheit konzentrieren, mit Plänen zur Einführung von zwei weiteren Programmen im Bereich öffentliche Gesundheit und Frauengesundheit. Das Unternehmen hat Vereinbarungen mit Appili Therapeutics und Evofem Biosciences für diese neuen Programme getroffen. Die Innovationsplattform von Aditxt zielt darauf ab, vielversprechende Gesundheitsinnovationen durch Zusammenarbeit mit Forschungseinrichtungen, Industriepartnern und Aktionären zu beschleunigen.
- None.
- None.
This week’s session will cover:
- Aditxt Overview and Transaction Updates: An update on the Company’s current position and progress regarding the Evofem and Appili transactions.
- Overview of Aditxt’s Current Programs: Updates on Aditxt’s two ongoing programs in immune and precision health.
- Year-End Roadmap: Insights into Aditxt’s plans and goals for the remainder of 2024.
- Q&A Segment: Amro Albanna will respond to questions submitted in advance.
Stakeholders can submit their questions for the upcoming sessions by Thursday, October 10, 2024 at 5:00 PM EDT to engagement@aditxt.com. To register for the session, please visit this link.
“Our stakeholders are key to our success,” said Amro Albanna, Co-Founder, Chairman, and CEO of Aditxt. “It is critical for us to communicate our status and plans effectively and continuously. Sessions like this allow us to keep our stakeholders informed and engaged, providing them with a clear understanding of our progress, challenges, and the potential of our programs and strategic initiatives.”
Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For the latter two programs, Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which focuses on infectious diseases, and a Merger Agreement with Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), which focuses on women’s health. Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing, and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each transaction with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.
About Aditxt, Inc.
Aditxt, Inc.® is an innovation platform dedicated to accelerating promising health innovations. Aditxt’s ecosystem of research institutions, industry partners, and shareholders collaboratively drives their mission to "Make Promising Innovations Possible Together." The innovation platform is the cornerstone of Aditxt’s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder’s voice is heard and valued and empowers collective progress.
Aditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women’s health. For these, Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which focuses on infectious diseases, and a Merger Agreement with Evofem Biosciences, Inc. (OTCQB: EVFM). Each program will be designed to function autonomously while collectively advancing Aditxt’s mission of discovering, developing, and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.
For more information, www.aditxt.com.
Follow us on:
LinkedIn: https://www.linkedin.com/company/aditxt
Facebook: https://www.facebook.com/aditxtplatform/
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s ability to finance and execute its strategic M&A initiatives; the Company’s ability to obtain the necessary funding and partner to commence clinical trials; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the Company’s ability to raise additional capital; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled “Risk Factors” in Aditxt’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241009619012/en/
Media Relations Contact:
Mary O’ Brien
mobrien@aditxt.com
(516) 753-9933
Source: Aditxt, Inc.
FAQ
When is Aditxt (ADTX) hosting its stakeholder update and Q&A session?
What topics will be covered in Aditxt's (ADTX) upcoming stakeholder update?
What new programs is Aditxt (ADTX) planning to introduce?
Which companies has Aditxt (ADTX) entered into agreements with for its new programs?
How can stakeholders submit questions for Aditxt's (ADTX) Q&A session?
